Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-05 07:15 |
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 9.3 KB | ||
| 2024-11-05 01:00 |
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 7.7 KB | ||
| 2024-07-29 07:15 |
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 8.6 KB | ||
| 2024-07-29 02:00 |
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 6.9 KB | ||
| 2024-07-22 07:15 |
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 10.8 KB | ||
| 2024-07-22 02:00 |
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 9.1 KB | ||
| 2024-07-08 07:15 |
Spexis AG: PARI Pharma GmbH announces termination of ColiFin license to EnBioti…
|
English | 10.0 KB | ||
| 2024-07-08 02:00 |
Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiot…
|
English | 8.4 KB | ||
| 2024-06-04 20:00 |
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 8.0 KB | ||
| 2024-06-04 02:00 |
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 6.4 KB | ||
| 2024-05-31 22:00 |
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 19.4 KB | ||
| 2024-05-31 02:00 |
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 16.6 KB | ||
| 2024-04-30 20:30 |
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 9.8 KB | ||
| 2024-04-30 02:00 |
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 8.2 KB | ||
| 2024-04-17 07:15 |
Spexis announces extension of moratorium, receipt of an additional payment rela…
|
English | 13.8 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
